Ben Stevens
Ben is the editor of Business of Cannabis. Since 2021, he has researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.
Ben Stevens · page 6
- Clinical Research
A Cannabis Flavonoid Stopped Up to 99% of Cancer-Cell Growth in Lab Tests
Standard Seed Corporation (SSC), a cutting edge AI botanical-research company, believes it has identified a compound native to cannabis which could inhibit the growth of cancer cells by over 90% in some of the most aggressive forms of cancer.
- CBD Market
CBD Brand Director Sentenced for Covid Loan Fraud and Money Laundering
The director of UK CBD brand Virtutum Limited, which traded as CBD Asylum in Hull, has been given a suspended prison sentence for fraud and money laundering.
- Medical Cannabis
Cannabis Use Among Teens Flat After German Partial Legalisation, But Medical Market Continues Rapid Expansion
Germany’s Cannabis Act (CanG) has not led to an increase in use among young people, according to new peer-reviewed research adding to the growing body of evidence contradicting the harms predicted by the reform’s critics.
- Hemp Industry
Bipartisan Bill Seeks to Overturn Intoxicating Hemp Ban and Regulate Multi-Billion Dollar Sector
The US intoxicating hemp market, thought to be worth around $28bn in annual sales, could yet be saved from a devastating ban set to be implemented in a matter of months.
- Clinical Research
Argent Trades Global Rights to Lead Cannabis Drug For Debt Relief in New $5.5m Deal
Argent BioPharma (RGT), formerly MGC Pharmaceuticals, has sold the global commercialisation rights of its leading epilepsy drug, CannEpil, in order to clear a sizable chunk of its debt.
- Prescribers & Clinics
Cantourage Bets on Own Brand to Defend Flower Margins
Cantourage Group SE has announced the launch of its first proprietary medical cannabis brand for the German market, in a meaningful pivot for the distributor.
- Medical Cannabis
Measuring What Matters: Why Outcomes Will Decide the Future of Cannabis Medicine
The UK medical cannabis sector has spent seven years arguing for access.
- Pharmaceutical
Ananda Pharma Doses First Patient in NIHR-Backed CIPN Trial
Ananda Pharma has dosed the first patient in the ACTiON trial, a Phase 2 NIHR-funded study evaluating MRX1, the company’s proprietary CBD-based oral solution, as a treatment for chemotherapy-induced peripheral neuropathy (CIPN), a debilitating nerve-damage condition caused by chemotherapy for which no effective therapies currently exist.
- US & Canada
DEA Rescheduling Hearing Closes as States’ Own Witness Concedes Regulation Reduces Crime
The Drug Enforcement Administration’s (DEA) administrative hearing on cannabis rescheduling saw both sides make their closing arguments on Wednesday, July 15, bringing the 17-day proceedings to a broadly positive close.
- Cultivation
Rua Bioscience Signs its Largest-Ever Export Deal With Unnamed UK Cannabis Clinic
New Zealand-listed Rua Bioscience (NZX: RUA) has agreed a sales and distribution deal with one of the UK’s largest medicinal cannabis clinic and distribution businesses, expected to generate NZ$10m in revenue over two years, the company’s largest export contract to date.
- Public Markets
Ascend Wellness Joins Uplisting Wave With DEA Registration and Stock Split Plans
Ascend Wellness Holdings (CSE: AAWH-U.CN / OTCQX: AAWH) has become the latest US multi-state cannabis operator to target an uplisting to a major exchange, following the landmark entrance of Trulieve (TRLV) onto the New York Stock Exchange (NYSE) last month.
- US & Canada
US Rescheduling Hearing Nears End as Opposition’s Own Witness Acknowledges Cannabis Fits Schedule III Standard
Tomorrow (July 15, 2026) the landmark administrative hearing on US cannabis rescheduling will come to a close.
